Trial designs for targeted therapies.
This is a discussion of the paper 'Making efficient use of patients in designing phase III trials investigating simultaneously a set of targeted therapies with different targets' by Werner Vach and Rene dePont Christensen.
Thompson
Simon G
SG
MRC Biostatistics Unit, Institute of Public Health, Robinson Way, Cambridge CB2 2SR, UK. simon.thompson@mrc-bsu.cam.ac.uk
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001699:Biometry / Q000379:methods*; D017326:Clinical Trials, Phase III as Topic / Q000379:methods*; D003627:Data Interpretation, Statistical; D016503:Drug Delivery Systems / Q000379:methods* / Q000706:statistics & numerical data*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000453:epidemiology; D018579:Patient Selection; D012107:Research Design
D000970:Antineoplastic Agents